Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab versus best available therapy in chronic graft-versus-host disease after at least 2 prior systemic therapies
NL-OMON59368Phase 3Completed
- Sponsor
- Incyte
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of axatilimab in chronic graft-versus-host disease (cGVHD) (2 arms), sponsored by Incyte. Primary endpoint: Overall response at 6 months. Started Jun 2025; status: completed.
02
Drugs
axatilimab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NL-OMON59368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59368.